Ascendis Pharma A/S announced that the U.S. Food & Drug Administration has accepted for review the Company’s resubmitted New Drug Application for TransCon PTH for the treatment of adult patients with hypoparathyroidism. The agency considered the resubmission a complete, class 2 response and set a Prescription Drug User Fee Act goal date of May 14, 2024. In the United States, TransCon PTH for adult patients with hypoparathyroidism.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ASND:
- FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism
- Ascendis Pharma enters exclusive license agreement with Teijin for TransCon
- Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan
- Ascendis Pharma price target raised to $124 from $115 at BofA
- Ascendis Pharma announces EC approval of YORVIPATH